ASH 2022 | V-FAST subgroup analysis: CPX-351 plus midostaurin for newly diagnosed FLT3-mutated AML
Mark Levis
• 11 Dec 2022
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses intensive treatment strategies involving CPX-351 and targeted agents for acute myeloid leukemia (AML). Dr Levis highlights that in a subgroup analysis of the V-FAST master trial (NCT04075747), the combination of CPX-351 and midostaurin was well tolerated and had good complete remission (CR) rates in patients with newly diagnosed FLT3-mutated AML. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
